In recent news, **Charles River Laboratories International CRL** announced plans to **sell off underperforming business segments** following a strategic review. This comes amidst a series of investigations initiated by former Louisiana Attorney General, Kahn Swick & Foti, LLC. Despite recent volatility and a rebound in share price, mainly due to a **$1B buyback plan**, CRL's ongoing losses challenge the bullish narrative. Their Q3 reports beat estimates on revenue but were met with mixed responses due to an insufficient growth hampering the share price. CRL has announced collaborations aimed at boosting innovation prospects and redefining its competitive edge through new drug discovery and non-animal testing, which contribute to analysts, such as Baird, upgrading CRL to **outperform** from neutral. However, there has been a call for CRL shareholders to make contact to discuss their rights, possibly due to concerns over strategic actions and controversies with non-core asset divestment. Some collaborations, like ones with PICI and CHLA, have expanded the company's capabilities in oncology.
Charles River Laboratories International CRL News Analytics from Fri, 11 Apr 2025 07:00:00 GMT to Sat, 08 Nov 2025 04:16:52 GMT -
Rating 2
- Innovation 3
- Information 5
- Rumor 1
